AbbVie

News

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S

News

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.

News

CVS Health launches private label biosimilars unit

CVS Health has made a move on the US biosimilars category with the launch of Cordavis, a new business unit that will work with other drugmakers to bring private-label bios

News

Samsung seeks 'interchangeable' label for Humira biosimilar

While there are already a number of biosimilars of AbbVie's big-selling Humira on the US market, so far, only one – Boehringer Ingelheim's

News

AbbVie nears EU nod for DLBCL drug epcoritamab

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an a

News

First Wave faces choppy waters with cystic fibrosis drug

First Wave BioPharma can’t seem to catch a break in its efforts to bring a new drug to market for pancreatic insufficiency problems that affect most patients with cystic f

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

FDA starts swift review of Regeneron’s CD20 bispecific

CVS Health launches private label biosimilars unit

Samsung seeks 'interchangeable' label for Humira biosimilar

AbbVie nears EU nod for DLBCL drug epcoritamab

First Wave faces choppy waters with cystic fibrosis drug

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

AbbVie

Editor's Picks